Risk of Posterior Staphyloma in Highly Myopic Europeans : From Epidemiology to Anatomy.
Condition(s) studied
Investigational drug(s) / intervention(s)
blood sampling for DNA: Blood sampling for DNA and serum and plasma colection and PBMC
Study summary
In this cross-sectionnal study the aim is to increase the understanding of posterior staphyloma through a unique European consortium. Therefore, all eligible patients that either visit the outpatient clinic at Radboud in Nimegen, the Netherlands, or visit University Hopital Puerta de HierroMajadahonda in Madrid, Spain, or visit University Hospital Cochin in Paris, France, and after consenting, will be included.
600 high myopic European cases are expecting. A standardized protocol in all centers in order to create a uniform dataset.
Besides the standard of care, blood samples will be collected.
All data collected will be stored in an onlie Castor database
Eligibility
Primary outcome measure(s)
- Differential gene expression between myopic patients with and without staphyloma — Through study completion, an average of 1 year.
Genetic analysis
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Cochin Hospital | Paris | France | Recruiting |
More Assistance Publique - Hôpitaux de Paris trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06949579 on ClinicalTrials.gov ↗ ← All trials in France